# Acoramidis

Drug · id `cardio:acoramidis` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Attruby; Acoramidis hydrochloride

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

Acoramidis is the medicine in Attruby, a tablet sold as acoramidis hydrochloride. The US label calls it a transthyretin stabilizer and says it is a selective stabilizer of transthyretin (TTR), the protein involved in transthyretin amyloidosis. The label gives its indication as the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults, to reduce cardiovascular death and cardiovascular-related hospitalization. The atlas holds no trial results for it.

## Technical summary

RxNorm ingredient 2698312 (acoramidis); the label names the salt acoramidis hydrochloride (RxNorm 2698313), whose UNII VY9C88C2NV is a broad match to the ingredient. RxClass lists the FDA established pharmacologic class Transthyretin Stabilizer, so the record is filed under the class page. MeSH has no descriptor for acoramidis (an exact-label lookup returned an empty list on 2026-11-19). The label read is the BridgeBio Pharma, Inc. label for Attruby, application NDA216540, effective 2026-06-29 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with one product. The record read has no boxed warning section. This page records the label indication, the class and the mechanism sentences only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, as described in the US label of Attruby

Recipient: Recipient not specified; Population: Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), as the indications section of the label describes them. The passages read give no other age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Attruby (acoramidis hydrochloride tablets; BridgeBio Pharma, Inc., application NDA216540; the version dated 2026-06-29 in openFDA) calls the product a transthyretin stabilizer. It lists the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular death and cardiovascular-related hospitalization, as the indication.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), as the indications section of the label describes them. The passages read give no other age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label has no boxed warning in the record read. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-19
- Sources:
  1. Background: openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording (Regulator, edition The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22913552ef-875d-4cb7-bf05-a7d20a394c38%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T00:29:51Z. Source state: Current. Version fingerprint: 438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f.
     How it applies: Application number of the label read, NDA216540.
  2. Background: openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording (Regulator, edition The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22913552ef-875d-4cb7-bf05-a7d20a394c38%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T00:29:51Z. Source state: Current. Version fingerprint: 438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f.
     How it applies: Effective date of the label text read, 20260629.
  3. Supports: openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording (Regulator, edition The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22913552ef-875d-4cb7-bf05-a7d20a394c38%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], highlights sentence. Retrieved 2026-11-19T00:29:51Z. Source state: Current. Version fingerprint: 438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-ACO-LB-04).
  4. Supports: openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording (Regulator, edition The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22913552ef-875d-4cb7-bf05-a7d20a394c38%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], highlights sentence, benefit. Retrieved 2026-11-19T00:29:51Z. Source state: Current. Version fingerprint: 438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-ACO-LB-05).

## Connected pages

- Acoramidis is a transthyretin stabilizer (FDA established pharmacologic class in RxClass): Transthyretin stabilizers and transthyretin-directed RNA interaction medicines (`cardio:transthyretin-directed-medicines`)
- FDA label lists the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults, to reduce cardiovascular death and cardiovascular-related hospitalization, as an indication: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`) [a claim, not a settled fact; see claim `cardio:claim-fda-attruby-label-indications` and its context]
- Both labels call the medicine a stabilizer of transthyretin, and both list the cardiomyopathy of transthyretin-mediated amyloidosis as the indication: Tafamidis (`cardio:tafamidis`)
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 9eed0e120ec3b2f3557d5ed715dbb373f512c83990889481de2ce7da1ec29ac7
Last substantive edit: 2026-11-19
Evidence last checked: 2026-11-19
